Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review

BackgroundPatients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of p...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Jiayi Li, Xin Zhang, Zhuanzhuan Mu, Di Sun, Yuqing Sun, Yansong Lin
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2022-08-01
Cyfres:	Frontiers in Immunology
Pynciau:	radioactive iodine refractory differentiated thyroid cancer combination immunotherapy multitargeted kinase inhibitors plus PD-1/PD-L1 inhibitors therapy apatinib plus camrelizumab treatment
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.943916/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!